Sanofi to discontinue Insuman® insulins over upcoming months

insuman

In February 2023, Sanofi, manufacturers of the human insulin range Insuman® announced that production and sales of this range will end within the next four months.

Sanofi is set to discontinue the following products by the end of February:

  • Insuman® Basal 100 IU/ml suspension for injection in a cartridge (Insulin isophane human)
  • Insuman® Comb 25 100 IU/ml suspension for injection in a cartridge (Insulin biphasic isophane human).

The company is also discontinuing the following products by the end of May and June:

  • Insuman® Rapid 100 IU/ml solution for injection in a cartridge (Insulin soluble human) – May 2023
  • Insuman® Basal SoloStar 100 IU/ml suspension for injection in a pre-filled pen (Insulin isophane human) – June 2023
  • Insuman® Comb 25 SoloStar 100 IU/ml suspension for injection in a pre-filled pen (Insulin biphasic isophane human) – June 2023.

Fewer than 1% of people receiving insulin in the UK are prescribed Insuman® regular human, isophane or isophane pre-mixed insulins, as people with diabetes are increasingly managed with modern analogue insulins. People currently receiving any of the Insuman® presentations, should be moved to a suitable alternative treatment under the supervision of their prescribing clinician as soon as possible.

Back to news archive